Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study

Rheumatology (United Kingdom)

Volumn 53, Issue 6, 2014, Pages 1087-1094

  Fagerli, Karen M ^a   van der heijde, Désirée ^a,b   Heiberg, Marte S ^a   Wierød, Ada ^c   Kalstad, Synøve ^d   Rødevand, Erik ^e   Mikkelsen, Knut ^f   Kvien, Tore K ^a   Lie, Elisabeth ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VESTRE VIKEN HOSPITAL TRUST   (Norway)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^f Hospital for Rheumatic Diseases   (Norway)

Author keywords

Ankylosing spondylitis; DMARD; Spondyloarthritis; Sulfasalazine; TNF inhibitor; Treatment

Indexed keywords

SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; AXIAL SPONDYLOARTHRITIS; DISEASE DURATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; JOINT SWELLING; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SPONDYLARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; DRUG SUBSTITUTION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS; SULFASALAZINE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900831666     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket450     Document Type: Article

References (22)

1. Braun J, van den Berg R, Baraliakos X et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70: 896-904.
2. van der Heijde D, Sieper J, Maksymowych WP et al. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-8.
3. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005.
4. Clegg DO, Reda DJ, Weisman MH et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2004-12.
5. Nissila M, Lehtinen K, Leirisalo-Repo M et al. Sulfasalazine in the treatment of ankylosing spondylitis. A twentysix- week, placebo-controlled clinical trial. Arthritis Rheum 1988;31:1111-6.
6. Braun J, Zochling J, Baraliakos X et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006;65:1147-53.
7. van den Berg R, Baraliakos X, Braun J et al. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and nonbiologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Rheumatology 2012;51:1388-96.
8. Brandt J, Khariouzov A, Listing J et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
9. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
10. Inman RD, Davis JC Jr, Heijde D et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
11. van der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
12. Song IH, Hermann K, Haibel H et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011;70:590-6.
13. Braun J, Pavelka K, Ramos-Remus C et al. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol 2012;39:836-40.
14. Pincus T, Summey JA, Soraci SA Jr et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53.
15. Brazier J, Roberts J, Deverill M. The estimation of a preference- based measure of health from the SF-36. J Health Econ 2002;21:271-92.
16. van der Heijde D, Lie E, Kvien TK et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:1811-8.
17. Garrett S, Jenkinson T, Kennedy LG et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
18. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
19. Kiltz U, Baraliakos X, Karakostas P et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res 2012;64: 1415-22.
20. van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
21. Sieper J, van der Heijde D, Dougados M et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebocontrolled trial (ABILITY-1). Ann Rheum Dis 2013;72: 815-22.
22. Kristensen LE, Karlsson JA, Englund M et al. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res 2010;62: 1362-9.